TRUDHESA™ New Drug Application (NDA) Under Review by U.S. Food & Drug Administration (FDA) with PDUFA Target Action Date of September 6, 2021
Preparations On Track for Potential TRUDHESA Launch in the Fourth Quarter of 2021
Increased Cash Position and Extended Runway through 2022 Following $50 Million Debt Facility Agreement with Oxford Finance LLC and Silicon Valley Bank
Impel to Host Investor Conference Call Today at 8:30 a.m. ET
SEATTLE, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.
“The first half of 2021 has been marked by significant milestones, which we believe have positioned Impel well for a successful commercial launch of TRUDHESA™ in the fourth quarter, subject to regulatory approval. In addition, our pre-launch activities together with ongoing interactions with patients and healthcare providers continue to reinforce our view that significant unmet needs remain in the treatment of acute migraine,” said Adrian Adams, chairman and chief executive officer of Impel NeuroPharma. “Following the recent closing of our debt financing agreement, we are confident that Impel’s strengthened balance sheet will provide us not only with the resources for a successful launch of TRUDHESA, but also the continued development of INP105 for the potential treatment of agitation and aggression in autism.”
Recent Corporate Highlights:
Second Quarter 2021 Financial Results:
Conference Call Information
Impel NeuroPharma will host a live conference call and webcast at 8:30 a.m. ET today to discuss second quarter 2021 financial results and a corporate update. The conference call may be accessed by dialing 877-295-2648 (domestic) or 470-495-9487 (international) and referring to conference ID 3073333. A live webcast of the event will be available on the Investors section of the Impel NeuroPharma website at https://investors.impelnp.com/. A replay of the webcast and accompanying slides will be available on the Impel NeuroPharma website following the event.
Non-GAAP Financial Measures
We have provided in this press release certain financial information that has not been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”). Our management uses these non-GAAP financial measures internally in analyzing our financial results and believes that use of these non-GAAP financial measures is useful to investors as an additional tool to evaluate ongoing operating results and trends and in comparing our financial results with other companies in our industry, many of which present similar non-GAAP financial measures. Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable financial measures prepared in accordance with GAAP and should be read only in conjunction with our consolidated financial statements prepared in accordance with GAAP. A reconciliation of our historical non-GAAP financial measures to the most directly comparable GAAP measures has been provided in the financial statement tables included in this press release, and investors are encouraged to review these reconciliations.
About Impel NeuroPharma:
Impel NeuroPharma, Inc. is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company’s strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD®) system with well-established therapeutics, including INP104 for the acute treatment of migraine, INP105 for the acute treatment of agitation in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.
About TRUDHESA™:
Impel NeuroPharma is developing TRUDHESA with the goal to be a transformative new therapy for the acute treatment of migraine headaches. TRUDHESA aims to optimize dihydroergotamine mesylate (DHE) for fast and lasting whole migraine relief, regardless of when in the migraine attack it is administered, without an injection. Importantly, TRUDHESA is designed to deliver a lower dose of DHE compared to other nasally administered, FDA-approved and investigational products. This may enable patients to benefit from the established efficacy of DHE, without the undesired side effects that may be experienced with delivery to the lower nasal space.
TRUDHESA utilizes Impel’s propellant-enabled POD technology to conveniently and consistently deliver optimal doses of DHE deep into the vascular rich upper nasal space, an ideal target for efficient drug administration. This may be particularly important for the majority of patients with migraine who experience nausea and/or vomiting during an attack, which presents limitations for the use of oral therapies, including triptans, CGRP inhibitors and ditans as well as other non-specific medications used for the acute treatment of migraine.
Cautionary Note on Forward-Looking Statements
This press release contains “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, timing of approval of Impel’s NDA for TRUDHESA™ and of Impel’s other regulatory submissions, timing of announcements of clinical results and clinical development activities of its product candidates, potential benefits and market opportunities of INP104 and its other product candidates and its cash runway. Forward-looking statements can be identified by words such as: “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “would,” “project,” “plan,” “expect” or the negative or plural of these words or similar expressions. These statements are subject to numerous risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including but not limited to, Impel’s ability to obtain and maintain regulatory approval of TRUDHESA and its other product candidates, its ability to execute its commercialization strategy for TRUDHESA its ability to develop, manufacture and commercialize its product candidates including plans for future development of its POD devices and plans to address additional indications for which Impel may pursue regulatory approval, whether results of preclinical studies or clinical trials will be indicative of the results of future trials, and the effects of COVID-19 on its clinical programs and business operations. Many of these risks are described in greater detail in Impel’s filings with the Securities and Exchange Commission. Any forward-looking statements in this press release speak only as of the date of this press release. Impel assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Impel, POD and the Impel logo are trademarks of Impel NeuroPharma, Inc. To learn more about Impel NeuroPharma, please visit our website at https://impelnp.com/.
| IMPEL NEUROPHARMA, INC. Condensed Consolidated Balance Sheet (In thousands, except share and per share data) | ||||||||
| June 30, 2021 | December 31, 2020 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 60,948 | $ | 7,095 | ||||
| Prepaid expenses and other current assets | 4,619 | 1,077 | ||||||
| Total current assets | 65,567 | 8,172 | ||||||
| Property and equipment, net | 3,408 | 3,700 | ||||||
| Other assets | 187 | 187 | ||||||
| Total assets | $ | 69,162 | $ | 12,059 | ||||
| Liabilities, redeemable convertible preferred stock, and stockholders’ equity (deficit) | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 5,461 | $ | 4,314 | ||||
| Accrued liabilities | 3,546 | 3,173 | ||||||
| Current portion of term debt | - | 417 | ||||||
| Convertible preferred stock warrant liabilities | - | 2,622 | ||||||
| Total Current Liabilities | $ | 9,007 | $ | 10,526 | ||||
| Long-term debt | 8,857 | 7,994 | ||||||
| Total liabilities | $ | 17,864 | $ | 18,520 | ||||
| Commitments and contingencies | ||||||||
| Redeemable convertible preferred stock, $0.001 par value; — and 204,198,489 shares authorized at June 30, 2021 and December 31, 2020 respectively; — and 202,009,981 shares issued and outstanding at June 30, 2021 and December 31, 2020 respectively; aggregate liquidation preference of $128,922 at December 31, 2020 | $ | - | $ | 127,039 | ||||
| Stockholders’ equity (deficit): | ||||||||
| Preferred stock, $0.001 par value; 10,000,000 and — shares authorized at June 30, 2021, and December 31, 2020, respectively | - | - | ||||||
| Common stock, $0.001 par value; 300,000,000 and 266,833,885 shares authorized at June 30, 2021, and December 31, 2020, respectively; 19,470,914 and 755,478 shares issued and outstanding at June 30, 2021, and December 31, 2020, respectively | 19 | - | ||||||
| Additional paid-in-capital | 216,314 | 4,762 | ||||||
| Accumulated Deficit | (165,035 | ) | (138,262 | ) | ||||
| Total stockholders’ equity (deficit) | $ | 51,298 | $ | (133,500 | ) | |||
| Total liabilities, redeemable convertible preferred stock, and stockholders’ equity (deficit) | $ | 69,162 | $ | 12,059 | ||||
| IMPEL NEUROPHARMA, INC. Condensed Consolidated Statement of Operations and Comprehensive Loss (in thousands) | |||||||||||||||
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | ||||||||||||||
| 2021 | 2020 | 2021 | 2020 | ||||||||||||
| Operating expenses: | |||||||||||||||
| Research and development | $ | 6,076 | $ | 6,832 | $ | 10,174 | $ | 13,391 | |||||||
| General and administrative | 8,862 | 6,127 | 14,633 | 9,374 | |||||||||||
| Total operating expenses | 14,938 | 12,959 | 24,807 | 22,765 | |||||||||||
| Loss from operations | (14,938 | ) | (12,959 | ) | (24,807 | ) | (22,765 | ) | |||||||
| Other income (expense) | (544 | ) | 36 | (1,966 | ) | 84 | |||||||||
| Loss before income taxes | (15,482 | ) | (12,923 | ) | (26,773 | ) | (22,681 | ) | |||||||
| Provision for (Benefit from) income taxes | - | (1 | ) | - | - | ||||||||||
| Net loss and comprehensive loss | (15,482 | ) | (12,922 | ) | (26,773 | ) | (22,681 | ) | |||||||
| Accretion on redeemable convertible preferred stock | 128 | 129 | 256 | ||||||||||||
| Net loss attributable to common stockholders | $ | (15,482 | ) | $ | (13,050 | ) | $ | (26,902 | ) | $ | (22,937 | ) | |||
| IMPEL NEUROPHARMA, INC. Earnings Per Share (in thousands, except share and per share amounts) | |||||||||||||||
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | ||||||||||||||
| 2021 | 2020 | 2021 | 2020 | ||||||||||||
| GAAP Basic and Diluted EPS | |||||||||||||||
| Numerator: | |||||||||||||||
| Net loss and comprehensive loss | $ | (15,482 | ) | $ | (12,922 | ) | $ | (26,773 | ) | $ | (22,681 | ) | |||
| Add: Accretion of preferred stock to redemption value | - | 128 | 129 | 256 | |||||||||||
| Net loss attributable to common shareholders | $ | (15,482 | ) | $ | (13,050 | ) | $ | (26,902 | ) | $ | (22,937 | ) | |||
| Denominator: | |||||||||||||||
| Weighted-average common shares outstanding, basic and diluted | 14,119,672 | 363,684 | 7,475,242 | 362,246 | |||||||||||
| Net loss per share attributable to common shareholders, basic and diluted | $ | (1.10 | ) | $ | (35.88 | ) | $ | (3.60 | ) | $ | (63.32 | ) | |||
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | ||||||||||||||
| 2021 | 2020 | 2021 | 2020 | ||||||||||||
| Non-GAAP loss per share information: | |||||||||||||||
| Numerator: | |||||||||||||||
| Historical net loss attributable to common shareholders | $ | (15,482 | ) | $ | (13,050 | ) | $ | (26,902 | ) | $ | (22,937 | ) | |||
| Accretion of preferred stock to redemption value | - | 128 | 129 | 256 | |||||||||||
| Change in fair value of convertible notes | - | - | 839 | - | |||||||||||
| Change in fair value of redeemable convertible preferred stock warrant liabilities | - | (35 | ) | 54 | (80 | ) | |||||||||
| Interest expense on convertible notes | 28 | - | 55 | - | |||||||||||
| Non-GAAP pro forma net loss attributable to common stockholders | $ | (15,454 | ) | $ | (12,957 | ) | $ | (25,825 | ) | $ | (22,761 | ) | |||
| Denominator: | |||||||||||||||
| Common shares outstanding: | |||||||||||||||
| Weighted average common shares outstanding | 14,119,672 | 363,684 | 7,475,242 | 362,246 | |||||||||||
| Shares issued in IPO | 1,523,810 | 5,333,334 | 3,418,048 | 5,333,334 | |||||||||||
| Common shares issued upon conversion of preferred stock | 3,601,657 | 12,541,340 | 8,078,855 | 12,541,340 | |||||||||||
| Automatic exchange of Avenue warrant | 30,761 | - | 68,999 | - | |||||||||||
| Issuance of shares of common stock pursuant to the cash and net exercise of warrants | 17,576 | 67,333 | 46,132 | 67,333 | |||||||||||
| Shares issued upon conversion of convertible notes | 159,881 | - | 358,629 | - | |||||||||||
| Weighted-average number of common shares outstanding used to compute pro forma net loss per share, as adjusted, basic and diluted | 19,453,357 | 18,305,691 | 19,445,905 | 18,304,253 | |||||||||||
| Pro forma net loss per share attributable to common shareholders, basic and diluted | $ | (0.79 | ) | $ | (0.71 | ) | $ | (1.33 | ) | $ | (1.24 | ) | |||
Contact:
Investor Relations:
Christina Tartaglia
Stern Investor Relations
Phone: (1) 212-362-1200
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Relations:
Melyssa Weible
Elixir Health Public Relations
Phone: (1) 201-723-5805
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.24 |
| Daily Volume: | 0 |
| Market Cap: | US$5.760M |
May 12, 2023 April 12, 2023 March 24, 2023 February 22, 2023 | |
Else Nutrition is changing the face of early childhood nutrition with clean, sustainable, plant-based products. The company has developed the world’s first whole plant-based infant formula that is targeting the $100+ billion global...
CLICK TO LEARN MORE
Surf Air Mobility is a regional air mobility platform expanding the category of regional air travel to reinvent flying through the power of electrification. In an effort to substantially reduce the cost and environmental impact of...
CLICK TO LEARN MORE